Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheena McCormack

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
The Lancet. HIV|December 2, 2022
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised controlled trialAlison J Rodger, Leanne McCabe, Andrew N Phillips, et al.
International Journal of Environmental Research and Public Health|January 16, 2020
Exploring Mechanisms of Action: Using a Testing Typology to Understand Intervention Performance in an HIV Self-Testing RCT in England and WalesT Charles Witzel, Peter Weatherburn, Adam Bourne, et al.
Vaccine|May 27, 2008
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc ConsortiumPierre-Alexandre Bart, Ruth Goodall, Tristan Barber, et al.
Eclinicalmedicine|March 8, 2021
Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and WalesT Charles Witzel, Talen Wright, Leanne McCabe, et al.
Microorganisms|November 7, 2020
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African VolunteersFrank Msafiri, Agricola Joachim, Kathrin Held, et al.
Plos One|May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I TrialAgricola Joachim, Asli Bauer, Sarah Joseph, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
The Lancet. HIV|December 1, 2023
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessmentAnn K Sullivan, John Saunders, Monica Desai, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
The Lancet. HIV|December 2, 2022
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised controlled trialAlison J Rodger, Leanne McCabe, Andrew N Phillips, et al.
International Journal of Environmental Research and Public Health|January 16, 2020
Exploring Mechanisms of Action: Using a Testing Typology to Understand Intervention Performance in an HIV Self-Testing RCT in England and WalesT Charles Witzel, Peter Weatherburn, Adam Bourne, et al.
Vaccine|May 27, 2008
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc ConsortiumPierre-Alexandre Bart, Ruth Goodall, Tristan Barber, et al.
Eclinicalmedicine|March 8, 2021
Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and WalesT Charles Witzel, Talen Wright, Leanne McCabe, et al.
Microorganisms|November 7, 2020
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African VolunteersFrank Msafiri, Agricola Joachim, Kathrin Held, et al.
Plos One|May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I TrialAgricola Joachim, Asli Bauer, Sarah Joseph, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
The Lancet. HIV|December 1, 2023
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessmentAnn K Sullivan, John Saunders, Monica Desai, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
Pageof 12